Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia - Stein, Eytan M.; DiNardo, Courtney D.; Pollyea, Daniel A.; Fathi, Amir T.; Roboz, Gail J.; Altman, Jessica K.; Stone, Richard M.; DeAngelo, Daniel J.; Levine, Ross L.; Flinn, Ian W.; Kantarjian, Hagop M.; Collins, Robert; et al. (Blood, 2017)
Keywords: Adult; Aged; Aged, 80 and over; Aminopyridines - adverse effects; Aminopyridines - pharmacokinetics; Aminopyridines - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Bone Marrow - drug effects; Bone Marrow - metabolism; Bone Marrow - pathology; Clinical Trials and Observations; Enzyme Inhibitors - adverse effects; Enzyme Inhibitors - pharmacokinetics; Enzyme Inhibitors - therapeutic use; Female; Humans; Isocitrate Dehydrogenase - antagonists & inhibitors; Isocitrate Dehydrogenase - genetics; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - pathology; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - pathology; Triazines - adverse effects; Triazines - pharmacokinetics; Triazines - therapeutic use; Young Adult